☆ 4.3 Review

Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients

EXPERT OPINION ON DRUG SAFETY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Dermatology

Elderly patients with psoriasis: long-term efficacy and safety of modern treatments

Katerina Bakirtzi et al.

Summary: This study evaluated the efficacy and safety of biologicals and apremilast in elderly psoriatic patients. The results showed that biologicals and apremilast have adequate efficacy in this patient population, and the incidence and severity of reported adverse events are similar to those in younger patients.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice

A. Ruggiero et al.

Summary: The study indicated that three anti-IL-23 therapies are promising, safe, and effective options for elderly patients with psoriasis, with no significant differences found between them. However, more data is required to confirm these results and understand their role in the management of this patient group. Limitations of the study included small sample size and varied follow-up durations.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study

Angelo Ruggiero et al.

Summary: A study conducted in Italy comparing the effectiveness and safety of guselkumab and risankizumab in treating moderate-to-severe psoriasis found that both drugs showed similar efficacy and safety profiles, with no significant differences observed between the two treatments.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Article Dermatology

Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study

Matteo Megna et al.

Summary: This real-life study evaluated the long-term efficacy and safety of guselkumab in patients who previously failed anti-IL17 treatments. The results showed significant improvement in Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) at each follow-up, as well as improvement in Nail Psoriasis Severity Index (NAPSI) after 28 weeks. Only a small percentage of patients discontinued guselkumab due to secondary inefficacy.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

Matteo Megna et al.

Summary: Efficacy and safety of risankizumab were confirmed in the treatment of psoriasis, with significant improvements observed in both PASI and BSA, even in a challenging population of patients with multiple treatment failures.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection

Matteo Megna et al.

Summary: This study demonstrated the safety of secukinumab treatment in patients with psoriasis who have markers of hepatitis B and/or C infections when administered with dedicated prophylaxis.

CLINICAL DRUG INVESTIGATION (2022)

添加到收藏夹

Article Dermatology

Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study

Matteo Megna et al.

Summary: Recent knowledge on the key role of IL-23/17 axis in psoriasis has led to the development of new biologic drugs, such as risankizumab. This study aimed to assess the efficacy and safety of risankizumab in patients who previously failed anti-IL-17 treatments. The results showed a significant reduction in psoriasis severity and improvement in nail psoriasis severity. The study confirmed the effectiveness and safety of risankizumab in these patients.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Article Dermatology

Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study

Matteo Megna et al.

Summary: This real-life study compared the efficacy and safety of anti-IL23 drugs for psoriasis management, and found that guselkumab, tildrakizumab, and risankizumab showed comparable efficacy and safety profiles, with guselkumab and risankizumab appearing slightly more effective for palmoplantar lesions in the short term.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection

Matteo Megna et al.

Summary: This study evaluated the safety profile of secukinumab in psoriasis patients with latent tuberculosis infection, demonstrating that after 84 weeks of treatment, there were no cases of tuberculosis reactivation. Secukinumab was found to be safe and effective even in patients who did not receive chemoprophylaxis.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Letter Dermatology

Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: A single-center, retrospective cohort study

Urmi Khanna et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Letter Dermatology

Teledermatology: A useful tool also after COVID-19 era?

Matteo Megna et al.

JOURNAL OF COSMETIC DERMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications

Claudio Marasca et al.

Summary: Inflammatory skin diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, and acne, have a significant impact on quality of life. The introduction of novel therapies has shown positive effects on the management of these diseases. Teledermatology has improved access to specialized dermatology care for patients in remote areas and saved costs.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Dermatology

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting

Matteo Megna et al.

Summary: This study compared the efficacy and safety of Ixekizumab and Brodalumab in patients with psoriasis, and found that they were comparable in terms of effectiveness and safety.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Treating psoriasis in the elderly: biologics and small molecules

Matteo Megna et al.

Summary: Psoriasis prevalence in the elderly is increasing, requiring systemic treatments. However, conventional systemic agents have limitations, while biologics and small molecules are valuable options. Although elderly psoriasis patients are often excluded from trials and guidelines are lacking, real-world data support the efficacy and safety of biologics and small molecules in this population.

EXPERT OPINION ON BIOLOGICAL THERAPY (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis

Paolo Gisondi et al.

Summary: Current evidence suggests that the use of biologics in patients with moderate to severe plaque psoriasis does not increase the risk or worsen the outcome of SARS-CoV-2 infection. TNF alpha inhibitors may even provide protection against severe COVID-19. Additionally, biologic treatment does not seem to have a significant impact on the safety and response to SARS-CoV-2 vaccines in psoriatic patients. However, further research is needed due to the limitations of current studies.

EXPERT OPINION ON BIOLOGICAL THERAPY (2022)

添加到收藏夹

Editorial Material Biotechnology & Applied Microbiology

New frontiers in personalized medicine in psoriasis

Elisa Camela et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2022)

添加到收藏夹

Letter Dermatology

Reply to Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review by Ricardo JW et al.

Matteo Megna et al.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Letter Dermatology

Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics

Matteo Megna et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

添加到收藏夹

Letter Dermatology

Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real-life study

Angelo Ruggiero et al.

DERMATOLOGIC THERAPY (2022)

添加到收藏夹

Review Dermatology

Towards Personalized Medicine in Psoriasis: Current Progress

Elisa Camela et al.

Summary: Although innovative targeted therapies have revolutionized psoriasis treatment, there is still a lack of robust biomarkers for guiding treatment decisions. Further research is needed to establish a comprehensive panel of biomarkers that can accurately predict treatment response in psoriasis.

PSORIASIS-TARGETS AND THERAPY (2022)

添加到收藏夹

Article Dermatology

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study

Matteo Megna et al.

Summary: The safety and efficacy of Guselkumab in psoriasis have been confirmed through real-life studies. In this 3-year retrospective study, Guselkumab showed significant improvement in psoriasis severity and safety profile, making it an effective long-term treatment option for psoriasis.

PSORIASIS-TARGETS AND THERAPY (2022)

添加到收藏夹

Article Dermatology

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study

Matteo Megna et al.

Summary: Adalimumab and etanercept biosimilars are effective and safe for the treatment of moderate-to-severe psoriasis in elderly and children, with no significant differences in efficacy and safety between the two.

PSORIASIS-TARGETS AND THERAPY (2022)

添加到收藏夹

Article Dermatology

QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study

Matteo Megna et al.

Summary: Overall, the study found that 6.5% of psoriasis patients undergoing biologic treatment experienced QFT conversion over an average treatment duration of 3.2 years, with conversion typically occurring after around 34.05 months of treatment. Anti-TNF-alpha drugs, particularly adalimumab, were most commonly associated with QFT conversion, followed by anti-IL-12/23 and anti-IL-17 therapies.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Review Dermatology

Psoriasis: Comorbidities

Fumikazu Yamazaki

Summary: Psoriasis used to be considered a skin disease with complications related to diet and obesity, but it is now recognized as a systemic inflammatory disease with cytokines that can induce various other diseases. Individuals with psoriasis have higher incidences of cerebral and cardiovascular diseases and tend to die at a younger age. Clear guidelines have not yet been established for how much vascular lesion testing should be performed in patients with psoriasis.

JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Letter Dermatology

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?

Matteo Megna et al.

DERMATOLOGIC THERAPY (2021)

添加到收藏夹

Article Dermatology

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial

Luis Puig et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis

Gerd R. Burmester et al.

ADVANCES IN THERAPY (2020)

添加到收藏夹

Letter Dermatology

Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period

M. Megna et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

添加到收藏夹

Article Dermatology

A case of erythrodermic psoriasis successfully treated with guselkumab

Matteo Megna et al.

DERMATOLOGIC THERAPY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Safety concerns with current treatments for psoriasis in the elderly

Roberta Di Caprio et al.

EXPERT OPINION ON DRUG SAFETY (2020)

添加到收藏夹

Review Dermatology

Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review

Vijay Kumari Sandhu et al.

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2020)

添加到收藏夹

Review Oncology

Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis

Arnold Lee et al.

BIODRUGS (2020)

添加到收藏夹

Article Dermatology

Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period

M. Megna et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2020)

添加到收藏夹

Letter Dermatology

A case of severe psoriasis in a 84-year-old women successfully treated with ixekizumab

Lucia Gallo et al.

DERMATOLOGIC THERAPY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Safety update of etanercept treatment for moderate to severe plaque psoriasis

Anna Campanati et al.

EXPERT OPINION ON DRUG SAFETY (2020)

添加到收藏夹

Letter Dermatology

Apremilast efficacy and safety in elderly psoriasis patients over a 48-week period

M. Megna et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

添加到收藏夹

Review Dermatology

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Jashin J. Wu et al.

DERMATOLOGY AND THERAPY (2020)

添加到收藏夹

Article Geriatrics & Gerontology

Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis

Celine Phan et al.

DRUGS & AGING (2020)

添加到收藏夹

Article Geriatrics & Gerontology

Optimizing the Treatment of Moderate-to-Severe Psoriasis in Older Adults

Nico Shary et al.

DRUGS & AGING (2020)

添加到收藏夹

Article Dermatology

Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis

Celine Phan et al.

ACTA DERMATO-VENEREOLOGICA (2020)

添加到收藏夹

Review Dermatology

Safety of selective IL-23p19 inhibitors for the treatment of psoriasis

J. J. Crowley et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)

添加到收藏夹

Review Chemistry, Medicinal

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events

Smriti Subedi et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis

Nienke Z. Borren et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

添加到收藏夹

Article Geriatrics & Gerontology

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

Andreas Koerber et al.

DRUGS & AGING (2018)

添加到收藏夹

Article Dermatology

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-and placebo-controlled study (CIMPACT)

Mark Lebwohl et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

添加到收藏夹

Letter Dermatology

First case of secukinumab successful therapy in a very elderly psoriatic patient

F. Ricceri et al.

DERMATOLOGIC THERAPY (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly

Vito Di Lernia et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2018)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Kenneth B. Gordon et al.

LANCET (2018)

添加到收藏夹

Article Dermatology

Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study

A. Chiricozzi et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

Advances in treating psoriasis in the elderly with small molecule inhibitors

Abigail Cline et al.

EXPERT OPINION ON PHARMACOTHERAPY (2017)

添加到收藏夹

Article Dermatology

Biologic treatments for elderly patients with psoriasis

Mami Momose et al.

JOURNAL OF DERMATOLOGY (2017)

添加到收藏夹

Article Dermatology

European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC

A. Nast et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Kristian Reich et al.

LANCET (2017)

添加到收藏夹

Article Dermatology

Psoriasis in the mature patient: Therapeutic approach in the era of biologics

Krešimir Kostović et al.

CLINICS IN DERMATOLOGY (2017)

添加到收藏夹

Letter Dermatology

Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period

M. Megna et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2016)

添加到收藏夹

Review Pharmacology & Pharmacy

Efficacy and safety of infliximab in psoriatic patients over the age of 65

Andrea Chiricozzi et al.

EXPERT OPINION ON DRUG SAFETY (2016)

添加到收藏夹

Article Dermatology

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

K. A. Papp et al.

BRITISH JOURNAL OF DERMATOLOGY (2015)

添加到收藏夹

Article Dermatology

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

C. Paul et al.

BRITISH JOURNAL OF DERMATOLOGY (2015)

添加到收藏夹

Review Chemistry, Medicinal

Small Molecules in the Treatment of Psoriasis

Tiago Torres et al.

DRUG DEVELOPMENT RESEARCH (2015)

添加到收藏夹

Article Dermatology

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Kim Papp et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)

添加到收藏夹

Review Geriatrics & Gerontology

Managing Moderate-to-Severe Psoriasis in the Elderly

Nicola Balato et al.

DRUGS & AGING (2014)

添加到收藏夹

Article Dermatology

Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis

Mitsuha Hayashi et al.

JOURNAL OF DERMATOLOGY (2014)

添加到收藏夹

Article Dermatology

Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study

Maria Esposito et al.

DERMATOLOGY (2012)

添加到收藏夹

Article Dermatology

Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype?

Hyuck Hoon Kwon et al.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2012)

添加到收藏夹

Article Dermatology

Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation

Ivan S. Grozdev et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Psoriasis and its treatment with adalimumab

Ala Iaconi et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2010)

添加到收藏夹

Article Dermatology

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Alan Menter et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)

添加到收藏夹

Article Immunology

THE SAFETY OF ANTI-TNF AGENTS IN THE ELDERLY

A. Migliore et al.

INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2009)

添加到收藏夹

Review Dermatology

Psoriasis: epidemiology

Johann E. Gudjonsson et al.

CLINICS IN DERMATOLOGY (2007)

添加到收藏夹

Article Dermatology

Etanercept for the treatment of psoriasis in the elderly

Militello Giuseppe et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)

添加到收藏夹

Article Dermatology

Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis

F Sampogna et al.

BRITISH JOURNAL OF DERMATOLOGY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.